Longeveron FY2024 revenue up 237% to $2.4M; net loss narrows 25% to $16.0M

Longeveron Inc.

2024-FY EPS reported -$2.62 revenue$2,392,000

Total revenue $2.4M (FY2023: $0.7M) driven by Bahamas Registry Trial and new manufacturing contract.
Net loss $16.0M vs $21.4M in 2023; cash & equivalents $19.2M, runway into Q4 2025.
Pivotal ELPIS II HLHS trial >90% enrolled; enrollment expected to complete Q2 2025.
BLA submission for Lomecel-B (laromestrocel) in HLHS anticipated in 2026 if trial successful.
FDA meeting for mild Alzheimer’s disease pathway expected late Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.